Faruqi & Faruqi Investigates PepGen Class Action

Strategic Insights -

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (NASDAQ: PEPG) on behalf of investors who suffered losses exceeding $50,000 in the company's securities. The investigation focuses on the alleged false and misleading statements made by PepGen and its executives regarding the effectiveness and safety of its PGN-EDO51 treatment and the CONNECT2 study. The company's stock price dropped significantly following several press releases that disclosed safety concerns and clinical hold notices from the FDA.

Key Takeaways:

  • The investigation centers around PepGen's alleged false and misleading statements regarding PGN-EDO51 and the CONNECT2 study.
  • The class action complaint alleges that PepGen and its executives made false and/or misleading statements about the treatment's effectiveness and safety.
  • The company's stock price dropped by 32.69% on July 31, 2024, after a Stifel analyst noted that the treatment's dystrophin increase was below expectations.
  • PepGen's stock price also fell by 3.63% on December 16, 2024, after the FDA issued a clinical hold notice for the Company's Investigational New Drug application.
  • The Company's stock price dropped again by 21.74% on January 30, 2025, after PepGen disclosed safety concerns and the FDA's questions about the CONNECT2 study.
  • PepGen's stock price fell by 18.86% on March 4, 2025, after the Company announced its decision to temporarily pause the CONNECT2 study.
  • The class action complaint alleges that PepGen's executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material information.

Statistics:

  • July 31, 2024: PepGen's stock price declined by $5.55 per share, or 32.69% to close at $11.43 per share.
  • December 16, 2024: PepGen's stock price fell by $0.17 per share, or 3.63%, to close at $4.51 per share.
  • January 30, 2025: PepGen's stock price dropped by $0.40 per share, or 21.74%, to close at $1.44 per share.
  • March 4, 2025: PepGen's stock price fell by $0.53 per share, or 18.86%, to close at $2.28 per share.

Sources:

  • GLOBE NEWSWIRE (July 30, 2025)
  • Faruqi & Faruqi, LLP (www.faruqilaw.com)
  • COMTEX_467679247/2010/2025-07-30T17:41:00